130 Participants Needed

[18F]APN-1607 PET Imaging for Alzheimer's Disease

Recruiting at 3 trial locations
TC
PC
BN
Overseen ByBrad Navia
Age: 18+
Sex: Any
Trial Phase: Phase 2
Sponsor: APRINOIA Therapeutics, LLC
Must be taking: AD symptomatic treatment
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial uses a special imaging agent to study brain patterns in people with mild dementia, Alzheimer's disease, and healthy individuals. The agent helps highlight abnormal brain proteins. A similar imaging agent was recently approved for visualizing amyloid.

Who Is on the Research Team?

Industry Expert: David Russell

David Russell, M.D., Ph.D

Principal Investigator

Invicro

Are You a Good Fit for This Trial?

This trial is for men and women aged 50-85, who are either not able to have children or agree to use contraception. It's for those with mild to moderate Alzheimer's Disease (MDAD), AD dementia, or healthy without cognitive impairment. Participants must be in good physical health with no relevant medical issues.

Inclusion Criteria

Written informed consent must be obtained before any assessment is performed.
Has a clinical dementia rating (CDR) score of 0.
I am a woman who cannot become pregnant or will not be pregnant during the study.
See 7 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

PET Imaging

Participants undergo PET imaging using [18F]APN-1607 to assess uptake patterns

1 week
1 visit (in-person)

Follow-up

Participants are monitored for safety and effectiveness after imaging

1 week
1 visit (in-person)

What Are the Treatments Tested in This Trial?

Interventions

  • [18F]APN-1607
Trial Overview [18F]APN-1607 uptake patterns are being compared across individuals with MDAD, AD dementia, and healthy subjects. The goal is to see how this imaging agent behaves differently among these groups which could help in understanding and diagnosing Alzheimer's Disease.
How Is the Trial Designed?
1Treatment groups
Experimental Treatment
Group I: [18F]APN-1607Experimental Treatment1 Intervention
Subjects will undergo PET imaging using \[18F\]APN-1607.

Find a Clinic Near You

Who Is Running the Clinical Trial?

APRINOIA Therapeutics, LLC

Lead Sponsor

Trials
2
Recruited
170+

Aprinoia Therapeutics Inc.

Lead Sponsor

Trials
1
Recruited
130+
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security